\documentclass[a4paper,11pt] {article}
\hfuzz=100pt 
%\documentclass[a4paper,article,oneside,10pt]{memoir}
\usepackage[latin1]{inputenc}
\usepackage[T1]{fontenc}
%\usepackage[lucidasmallscale, nofontinfo]{lucimatx}
%\usepackage{times}
\usepackage{graphicx}
\usepackage{longtable}
\usepackage{here}
\usepackage{ctable}
\usepackage{pdflscape}
\usepackage{pst-tree}
\usepackage{longtable}
\usepackage{multirow}
\usepackage{dcolumn}
\usepackage{Sweave}
\usepackage{lscape}
\usepackage{geometry}
\usepackage{graphicx}
\usepackage{subfig}
\usepackage{caption}
%\usepackage[pdftex,bookmarks=true,bookmarksnumbered=true,
%            hypertexnames=false,breaklinks=true,
%            linkbordercolor={0 0 1}]{hyperref}

%--------------

%
%\usepackage{fancyhdr}
%\pagestyle{empty}
%\pagestyle{fancy}
%\fancyhf{}
%%\renewcommand{\chaptermark}[1]{\markboth{\bsc{\chaptername~\thechapter{} :} #1}{}}
%%\renewcommand{\sectionmark}[1]{\markright{\thesection{} #1}}
%%\lfoot{Confidential, for the exclusive use of DMC members}
%%\renewcommand{\footrulewidth}{0.4pt}
%%\renewcommand{\headrulewidth}{0.4pt}
%%\renewcommand{\thepage}{\arabic{\page}}
%\setcounter{tocdepth}{5} % Dans la table des matieres
%\setcounter{secnumdepth}{5} % Avec un numero.
%%\mainmatter
%\pagenumbering{arabic}\setcounter{page}{1}
%\rhead{\thepage}
%\lhead{\leftmark}
%%\renewcommand{\thesection}{\Roman{section}}
%%\renewcommand{\thesection}{\Roman{section}}
%%\renewcommand{\thesection}{\Roman{section}}
%%\renewcommand{\thesubsection}{\thesection .\Alph{subsection}}
%
%--------------
\begin{document}
\title{Rapport  d'analyses statistiques}
\author{Axelle Dupont, sbim, Hopital Saint Louis, Paris}
\date\today

%------------------------------------------------------------






%-------------------------------------------------------------





\input{Rapport-concordance}


\setkeys{Gin}{width=1\textwidth}
\maketitle

%\pagestyle{protoc}
\tableofcontents
\pagebreak[4]
\listoftables
\listoffigures
%\SweaveOpts{eval=TRUE,echo=false,fig=TRUE}


\pagebreak[4]
%\chapter{Objectif}

\section{Objectives}

The primary objective of the study was to assess the survival, the risk of relapse and GVHD  of patients who underwent allogenic sterm-cell transplantation (alloSCT) for aggressive T-cell lymphomas. 
The second objective was to determine the variables associated with these outcomes.

\section{Methods}

A  retrospective analysis was conducted.A descriptive analysis of the variables recorded was perfomed.Different endpoints were defined : death, Progression Free Survival (PFC). EFS was defined as death,progression/relapse,  grade 3-4 acute GVHD or extensive chronic GVHD.

Survival curves were estimated using Kaplan-Meier product-limit estimator.
Competing risk survival analysis methods were applied to estimate the cumulative incidence (CIF) of developing events over time from alloSCT. These methods allow for the fact that a patient may experience an event which is different from that of interest. These events are known as competing risk events, and may preclude the onset of the event of interest, or may modify the probability of the onset of that event.In particular, a transplanted patient may die before a relapse occurs. 

%Factors associated with overall sur-vival were analyzed using Cox proportional hazards models. The proportional hazards assumption was checked by examination of Schoenfeld residuals.
%For the different endpoints, univariable analyses were first carried out, then a multivariable analysis was used where all factors with P-value < 0.15 in the univariable analyses were considered. Factors where then sequentially removed from the adjusted model with a P-value cut- at 0.05. 
%Survival is presented as estimate and 95\% confidence interval (95\% CI).




\pagebreak[4]
\section{Results}





\subsection{Descriptive results}
 285 patients were initially selected.We excluded 1 patient that underwent two alloSCT. The final analysis was perfomed on 284 patients and 284 grafts.
 \subsubsection{Patients characteristics}
% latex table generated in R 3.3.2 by xtable 1.8-2 package
% Mon Jun 19 17:37:12 2017
\begin{longtable}{llll}
  \hline
Parameters & Values & N & Statistics* \\ 
  \hline
 &  & 284 &  \\ 
  Patient sex & Female & 93 & 32.75 \% \\ 
   & Male & 191 & 67.25 \% \\ 
  Age at diagnosis &  & 284 & 45.01(15;68) \\ 
  Stage at diagnosis & I & 13 & 6.47 \% \\ 
   & II & 17 & 8.46 \% \\ 
   & III & 45 & 22.39 \% \\ 
   & IV & 126 & 62.69 \% \\ 
   & NA & 83 &  \\ 
  Subtypes & AITL & 82 & 28.87 \% \\ 
   & ALCL ALK- & 20 & 7.04 \% \\ 
   & ALCL ALK? & 2 & 0.7 \% \\ 
   & ALCL ALK+ & 21 & 7.39 \% \\ 
   & ATLL & 16 & 5.63 \% \\ 
   & EATL & 3 & 1.06 \% \\ 
   & HS & 12 & 4.23 \% \\ 
   & LGL & 1 & 0.35 \% \\ 
   & NK leukemia & 1 & 0.35 \% \\ 
   & NK/T nasal & 16 & 5.63 \% \\ 
   & NOS & 110 & 38.73 \% \\ 
  Subtypes & NOS & 110 & 38.73 \% \\ 
   & AITL & 82 & 28.87 \% \\ 
   & ALCL & 43 & 15.14 \% \\ 
   & ATLL & 16 & 5.63 \% \\ 
   & NK/T nasal & 16 & 5.63 \% \\ 
   & Others & 17 & 5.99 \% \\ 
  Centres & angers & 8 & 2.82 \% \\ 
   & Becquerel[941] & 4 & 1.41 \% \\ 
   & C.H.R.U Brest[659] & 2 & 0.7 \% \\ 
   & caen & 4 & 1.41 \% \\ 
   & CHU clermond ferrand & 7 & 2.46 \% \\ 
   & Geneve & 6 & 2.11 \% \\ 
   & Gustave Roussy[666] & 3 & 1.06 \% \\ 
   & H A Michallon[270] & 5 & 1.76 \% \\ 
   & H Bretonneau[272] & 3 & 1.06 \% \\ 
   & H Charles Nicolle[932] & 1 & 0.35 \% \\ 
   & H Claude Huriez[277] & 8 & 2.82 \% \\ 
   & H de l`ARCHET I[523]nice & 3 & 1.06 \% \\ 
   & H E Herriot[671] & 5 & 1.76 \% \\ 
   & H Haut-Leveque[267] & 31 & 10.92 \% \\ 
   & H Hautepierre[672] & 11 & 3.87 \% \\ 
   & H Jean Minjoz[233] & 5 & 1.76 \% \\ 
   & H La Miletrie[264] & 5 & 1.76 \% \\ 
   & H Mondor Hematol[252] & 4 & 1.41 \% \\ 
   & H Necker[160] & 9 & 3.17 \% \\ 
   & H Percy[665] & 4 & 1.41 \% \\ 
   & H Purpan[624] & 8 & 2.82 \% \\ 
   & H Sud/Pontchaillou[661] & 7 & 2.46 \% \\ 
   & H Sud[955] & 1 & 0.35 \% \\ 
   & Hotel Dieu[253] & 32 & 11.27 \% \\ 
   & liege & 8 & 2.82 \% \\ 
   & limoges & 3 & 1.06 \% \\ 
   & montpellier & 10 & 3.52 \% \\ 
   & nancy & 1 & 0.35 \% \\ 
   & Paoli Calmettes[230] & 39 & 13.73 \% \\ 
   & Pellegrin-Enfants[978] & 1 & 0.35 \% \\ 
   & Pitie-Salpetrriere[262] & 8 & 2.82 \% \\ 
   & St Antoine[775] & 10 & 3.52 \% \\ 
   & St Etienne[250] & 4 & 1.41 \% \\ 
   & St Louis[207] & 24 & 8.45 \% \\ 
   \hline
\hline
\caption{Patients characteristics} 
\label{tab:condi}
\end{longtable} \subsubsection{Treatments before alloSCT}
% latex table generated in R 3.3.2 by xtable 1.8-2 package
% Mon Jun 19 17:37:12 2017
\begin{longtable}{llll}
  \hline
Parameters & Values & N & Statistics* \\ 
  \hline
 &  & 284 &  \\ 
  Previous auto & No & 191 & 67.25 \% \\ 
   & Yes & 93 & 32.75 \% \\ 
   Programme auto allo & No & 257 & 90.49 \% \\ 
   & Yes & 27 & 9.51 \% \\ 
  First graft relapse & No & 219 & 77.11 \% \\ 
   & Yes & 65 & 22.89 \% \\ 
   \hline
\hline
\caption{Treatments before alloSCT} 
\label{tab:avtg}
\end{longtable}\pagebreak
 \subsubsection{Transplant conditions}
% latex table generated in R 3.3.2 by xtable 1.8-2 package
% Mon Jun 19 17:37:12 2017
\begin{longtable}{llll}
  \hline
Parameters & Values & N & Statistics* \\ 
  \hline
 &  & 284 &  \\ 
  Age at graft &  & 284 & 46.97(16;69) \\ 
  Donor age &  & 263 & 28.76(1;54) \\ 
  Donor sex & Female & 114 & 40.71 \% \\ 
   & Male & 166 & 59.29 \% \\ 
   & NA & 4 &  \\ 
  Delay diagnosis and allo SCT &  & 284 & 717(89;9684) \\ 
  >12 months delay & NO & 149 & 52.46 \% \\ 
   & Yes & 135 & 47.54 \% \\ 
  Disease status at transplant & CR & 175 & 61.84 \% \\ 
   & PR & 76 & 26.86 \% \\ 
   & PD & 32 & 11.31 \% \\ 
   & NA & 1 &  \\ 
  Disease status at transplant & CR (?) & 7 & 2.47 \% \\ 
   & CR1 & 94 & 33.22 \% \\ 
   & CR2 & 61 & 21.55 \% \\ 
   & CR3 & 13 & 4.59 \% \\ 
   & PD & 32 & 11.31 \% \\ 
   & PR (?) & 13 & 4.59 \% \\ 
   & PR1 & 39 & 13.78 \% \\ 
   & PR2 & 18 & 6.36 \% \\ 
   & PR3 & 5 & 1.77 \% \\ 
   & PR4 & 1 & 0.35 \% \\ 
   & NA & 1 &  \\ 
  Karnofsky score &  & 263 & 90 [80;100] \\ 
  Karnofsky score & 100 & 92 & 34.98 \% \\ 
   & 40 & 1 & 0.38 \% \\ 
   & 50 & 4 & 1.52 \% \\ 
   & 60 & 1 & 0.38 \% \\ 
   & 70 & 9 & 3.42 \% \\ 
   & 80 & 70 & 26.62 \% \\ 
   & 90 & 86 & 32.7 \% \\ 
   & NA & 21 &  \\ 
  Karnofsky score & 100 & 92 & 34.98 \% \\ 
   & Unable to carry on normal activity & 15 & 5.7 \% \\ 
   & 80 & 70 & 26.62 \% \\ 
   & 90 & 86 & 32.7 \% \\ 
   & NA & 21 &  \\ 
  No of lines before alloSCT &  & 254 & 2.201(1;9) \\ 
  No of lines before alloSCT & 1 & 73 & 28.74 \% \\ 
   & 2 & 92 & 36.22 \% \\ 
   & 3 & 65 & 25.59 \% \\ 
   & >=4 & 24 & 9.45 \% \\ 
   & NA & 30 &  \\ 
  No of lines before alloSCT & >2 & 89 & 35.04 \% \\ 
   & 1 or 2 & 165 & 64.96 \% \\ 
   & NA & 30 &  \\ 
  HLA match & HLA mismatched & 53 & 18.66 \% \\ 
   & HLA matched & 231 & 81.34 \% \\ 
  HLA match & Alternative donnors & 53 & 18.66 \% \\ 
   & Identical sibling & 128 & 45.07 \% \\ 
   & Matched unrelated & 103 & 36.27 \% \\ 
  HLA match & Identical sibling & 128 & 45.07 \% \\ 
   & Matched unrelated & 103 & 36.27 \% \\ 
   & Mismatched relative & 7 & 2.46 \% \\ 
   & Mismatched unrelated & 13 & 4.58 \% \\ 
   & Unrelated CB & 33 & 11.62 \% \\ 
  Sex of donnor/patient & F/M & 74 & 26.52 \% \\ 
   & Others & 205 & 73.48 \% \\ 
   & NA & 5 &  \\ 
  CMV serostatus of donnor/patient & neg/neg & 91 & 32.5 \% \\ 
   & Others & 189 & 67.5 \% \\ 
   & NA & 4 &  \\ 
  Source of stem cells & BM & 49 & 17.25 \% \\ 
   & CB & 33 & 11.62 \% \\ 
   & PB & 202 & 71.13 \% \\ 
  TBI & No & 161 & 56.69 \% \\ 
   & Yes & 123 & 43.31 \% \\ 
  conditioning Intensity & MAC & 106 & 38.13 \% \\ 
   & NMA & 27 & 9.71 \% \\ 
   & RIC & 145 & 52.16 \% \\ 
   & NA & 6 &  \\ 
  Conditioning & BEAM & 1 & 0.36 \% \\ 
   & BEAM + Campath & 1 & 0.36 \% \\ 
   & BU CY  & 4 & 1.42 \% \\ 
   & BU CY + FLU+ ATG & 1 & 0.36 \% \\ 
   & BU CY ATG & 1 & 0.36 \% \\ 
   & EDX ATG & 0 & 0 \% \\ 
   & ENX TBI 2gray & 1 & 0.36 \% \\ 
   & FLU ATG & 3 & 1.07 \% \\ 
   & FLU BU 1+ ATG & 3 & 1.07 \% \\ 
   & FLU BU 2 & 1 & 0.36 \% \\ 
   & FLU BU 2+ ATG & 73 & 25.98 \% \\ 
   & FLU BU 3+ ATG & 21 & 7.47 \% \\ 
   & FLU BU 4+ ATG & 10 & 3.56 \% \\ 
   & FLU BU EDX & 8 & 2.85 \% \\ 
   & FLU BU EDX +ATG & 6 & 2.14 \% \\ 
   & FLU EDX & 1 & 0.36 \% \\ 
   & FLU EDX ATG & 3 & 1.07 \% \\ 
   & FLU EDX MEL & 1 & 0.36 \% \\ 
   & FLU ENX TBI 2gray & 24 & 8.54 \% \\ 
   & FLU ENX TBI 4gray & 2 & 0.71 \% \\ 
   & FLU ENX TBI 6gray & 1 & 0.36 \% \\ 
   & FLU ENX TBI 6gray + campath & 1 & 0.36 \% \\ 
   & FLU MEL & 12 & 4.27 \% \\ 
   & FLU MEL + campath & 4 & 1.42 \% \\ 
   & FLU MEL + Campath & 1 & 0.36 \% \\ 
   & FLU MEL ATG & 1 & 0.36 \% \\ 
   & FLU MEL TBI 2gray & 1 & 0.36 \% \\ 
   & FLU TBI 2gray & 21 & 7.47 \% \\ 
   & FLU TBI 2gray ATG & 1 & 0.36 \% \\ 
   & FLU Tbi 8 gray & 1 & 0.36 \% \\ 
   & MEL 140 TBI 10 gray & 1 & 0.36 \% \\ 
   & MEL TBI VP16 & 1 & 0.36 \% \\ 
   & TB2F & 2 & 0.71 \% \\ 
   & TBI 12 gray & 1 & 0.36 \% \\ 
   & TBI 2gray & 1 & 0.36 \% \\ 
   & TBI EDX & 49 & 17.44 \% \\ 
   & TBI EDX +ATG & 11 & 3.91 \% \\ 
   & TBI EDX FLU & 5 & 1.78 \% \\ 
   & Thiotepa etoposide TBI12 gray & 1 & 0.36 \% \\ 
   & NA & 3 &  \\ 
  Cells manipulation & No & 275 & 97.86 \% \\ 
   & Yes & 6 & 2.14 \% \\ 
   & NA & 3 &  \\ 
  Depletion & No & 275 & 98.57 \% \\ 
   & Partial T depletion & 4 & 1.43 \% \\ 
   & NA & 5 &  \\ 
  No of donnors & 1 & 261 & 91.9 \% \\ 
   & 2 & 23 & 8.1 \% \\ 
   \hline
\hline
\caption{Transplant conditions} 
\label{tab:g}
\end{longtable}
\pagebreak
\subsubsection{Post-AlloSCT Response}
% latex table generated in R 3.3.2 by xtable 1.8-2 package
% Mon Jun 19 17:37:12 2017
\begin{longtable}{llll}
  \hline
Parameters & Values & N & Statistics* \\ 
  \hline
 &  & 284 &  \\ 
  Agvhd & No & 141 & 49.65 \% \\ 
   & Yes & 143 & 50.35 \% \\ 
  Agvhd grade & No aGvHD present (Grade 0) & 141 & 49.65 \% \\ 
   & Grade I & 49 & 17.25 \% \\ 
   & Grade II & 46 & 16.2 \% \\ 
   & Grade III & 24 & 8.45 \% \\ 
   & Grade IV & 17 & 5.99 \% \\ 
   & Present, grade unknown & 7 & 2.46 \% \\ 
  Cgvhd & Early death & 41 & 14.44 \% \\ 
   & no & 146 & 51.41 \% \\ 
   & yes & 97 & 34.15 \% \\ 
  Cgvhd grade & Early death (100D) & 41 & 14.44 \% \\ 
   & Extensive & 38 & 13.38 \% \\ 
   & Limited & 55 & 19.37 \% \\ 
   & No cGvh & 146 & 51.41 \% \\ 
   & grade unknown & 4 & 1.41 \% \\ 
  Engrafted & Early death (30D) & 5 & 1.76 \% \\ 
   & Engrafted & 271 & 95.42 \% \\ 
   & Lost graft & 2 & 0.7 \% \\ 
   & No engraftment & 6 & 2.11 \% \\ 
  Cause of death & HSCT-GVHd & 21 & 19.63 \% \\ 
   & HSCT-GVHd + infection & 3 & 2.8 \% \\ 
   & HSCT-infection & 27 & 25.23 \% \\ 
   & HSCT-toxicity & 4 & 3.74 \% \\ 
   & HSCT related & 3 & 2.8 \% \\ 
   & HSCT related ILD & 1 & 0.93 \% \\ 
   & HSCT related MAT & 1 & 0.93 \% \\ 
   & HSCT related MOF & 2 & 1.87 \% \\ 
   & HSCT related MVO & 1 & 0.93 \% \\ 
   & HSCT related pneumopathie interstititelle & 2 & 1.87 \% \\ 
   & HSCT related PTLD & 1 & 0.93 \% \\ 
   & HSCT related SDRA & 1 & 0.93 \% \\ 
   & Other & 1 & 0.93 \% \\ 
   & Relapse or progression of original disease & 37 & 34.58 \% \\ 
   & Secondary malignancy & 1 & 0.93 \% \\ 
   & Unknown & 1 & 0.93 \% \\ 
   & NA & 177 &  \\ 
  Best reponse after SCT & CR & 245 & 86.88 \% \\ 
   & Not evaluable & 4 & 1.42 \% \\ 
   & Not evaluated & 3 & 1.06 \% \\ 
   & PD & 14 & 4.96 \% \\ 
   & PR & 16 & 5.67 \% \\ 
   & NA & 2 &  \\ 
  Relapse/progression & Continuous progression & 28 & 9.93 \% \\ 
   & No & 217 & 76.95 \% \\ 
   & Non applicable  & 3 & 1.06 \% \\ 
   & Yes & 34 & 12.06 \% \\ 
   & NA & 2 &  \\ 
   \hline
\hline
\caption{Post-AlloSCT Response} 
\label{tab:pg}
\end{longtable}


\pagebreak[4]
\newgeometry{bmargin=1cm}
\begin{landscape}





\end{landscape}

\restoregeometry

\subsection{Survival analysis in all patients}
Median overall-survival from the date of AlloSCT was 20.18 (range 0.03 to 112.83). OS at 1 year was 0.68 (95 \% 0.62 - 0.73), was 0.64 (95 \% 0.58 - 0.7) at 2 years.OS at 4 years was 0.57 (95 \% 0.5 - 0.63).
\begin{figure}[h]
\begin{center}
\includegraphics{Rapport-fig1}
\end{center}
\caption{Overall survival}
\label{fig1}
\end{figure}

\pagebreak
CIF for relapse/progression at 1 years was 0.18 (95 \% 0.13 - 0.23), at 2 years  0.19 (95 \% 0.15 - 0.24).
CIF for death without relapse or progression at 1 year was 0.19 (95 \% 0.14 - 0.24), at 2 years  0.22 (95 \% 0.17 - 0.27). 

\begin{figure}[h]
\begin{center}
\includegraphics{Rapport-fig6}
\end{center}
\caption{CIF of relapse or progression and death without relapse or progression}
\label{fig6}
\end{figure}


\pagebreak
PFS at 1 year was 0.63 (95 \% 0.57 - 0.69), was 0.59 (95 \% 0.53 - 0.65) at 2 years. PFS at 4 years was 0.52 (95 \% 0.45 - 0.59).

%\begin{figure}[h]
%\begin{center}
%\end{center}
%\caption{Progression-free survival}
%\label{fig3}
%\end{figure}

EFS at 1 year was 0.49 (95 \% 0.44 - 0.56), was 0.47 (95 \% 0.41 - 0.54) at 2 years. EFS at 4 years was 0.43 (95 \% 0.37 - 0.5).

\begin{figure}[h]
\begin{center}
\includegraphics{Rapport-fig2}
\end{center}
\caption{Event-free survival and Progression free survival}
\label{fig2}
\end{figure}



\pagebreak
CIF for related HSCT death at 1 years was 0.2, at 2 years  0.23.
CIF for non-related HSCT Death at 1 year was 0.12, at 2 years  0.13.
\begin{figure}[h]
\begin{center}
\includegraphics{Rapport-fig5}
\end{center}
\caption{CIF of Related HSCT Death and Non-related HSCT Death}
\label{fig5}
\end{figure}

\begin{center}
\includegraphics[width=0.8\textwidth]{C:/Users/adupont/Documents/projetstlouis/scripts/Rapport-fig981.pdf}
\captionof{figure}{CIF of GVHD and Death without GVHD (acute or chronic)}

\end{center}



\pagebreak
\subsection{Survival analysis after a complete remisson post alloSCT}
245 patients whith a complete remission were included.


OS at 1 year was 0.74 (95 \% 0.68 - 0.8), was 0.7 (95 \% 0.64 - 0.76) at 2 years. OS at 4 years was 0.62 (95 \% 0.56 - 0.7).
\\
\begin{center}
\includegraphics[width=0.5\textwidth]{C:/Users/adupont/Documents/projetstlouis/scripts/Rapport-figg.pdf}
\captionof{figure}{OS in patients with a complete remission post alloSCT}

\pagebreak
CIF for relapse at 1 year was 0.12 (95 \% 0.07 - 0.16), at 2 years  0.13 (95 \% 0.09 - 0.18). CIF for death without relapse  at 1 year was 0.19 (95 \% 0.14 - 0.24), at 2 years  0.22 (95 \% 0.17 - 0.28). 


\begin{center}
\includegraphics[width=0.8\textwidth]{C:/Users/adupont/Documents/projetstlouis/scripts/Rapport-fig7.pdf}
\captionof{figure}{CIF of relapse and death without relapse (in patients with a complete remission post alloSCT)}

\end{center}



%\end{center}
%\begin{center}
%\includegraphics[width=0.5\textwidth]{C:/Users/adupont/Documents/projetstlouis/scripts/Rapport-figg2.pdf}
%\captionof{figure}{PFS in patients with a complete remission post alloSCT}

\end{center}
\begin{center} 
 
\includegraphics[width=0.5\textwidth]{C:/Users/adupont/Documents/projetstlouis/scripts/Rapport-xcube.pdf}
\captionof{figure}{RFS and EFS in patients with a complete remission post alloSCT}



%\end{center}



\pagebreak

\begin{center}
\includegraphics[width=0.8\textwidth]{C:/Users/adupont/Documents/projetstlouis/scripts/Rapport-fig99.pdf}
\captionof{figure}{CIF of Related HSCT Death and Non-related HSCT Death (in patients with a complete remission post alloSCT)}

\end{center}
\pagebreak
\begin{center}
\includegraphics[width=0.8\textwidth]{C:/Users/adupont/Documents/projetstlouis/scripts/Rapport-fig98.pdf}
\captionof{figure}{CIF of GVHD and Death without GVHD (acute or chronic)(in patients with a complete remission post alloSCT)}

\end{center}

%\subsection{Univariate Analysis}




% latex table generated in R 3.3.2 by xtable 1.8-2 package
% Fri May 26 14:16:17 2017




\end{document}
